Risankizumab Effectiveness and Safety in Crohn's Disease: Real-world Data From a Large Tertiary Center

Abstract

L23 is a recognized cytokine involved in the pathogenesis of inflammatory bowel diseases (IBDs).¹ The first IL23-targeting agent that became available for clinical use in IBD was Ustekinumab, a monoclonal antibody that targets p40, a shared subunit of both IL23 and IL12.^2,3 Risankizumab (Skyrizi; Abbvie) is a humanized IgG1 monoclonal antibody which binds to the p19 subunit and therefore selectively inhibits IL23.⁴ In June 2022, it was approved by the United States Food and Drug Administration for the treatment of moderately to severely active Crohn's disease (CD). Here, we describe the effectiveness and safety of risankizumab throughout the induction period in a real-world setting of a large tertiary center.